Abstract: Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype characterized by the absence of hormone receptors and HER2, making it unresponsive to traditional hormone therapies and necessitating the discovery of novel targeted treatments. Regulated cell death (RCD) pathways, including apoptosis and autophagy, have emerged as critical targets for small-molecule interventions. Torin 1, a potent mammalian target of rapamycin (mTOR) inhibitor, has demonstrated significant potential in oncology research, particularly for TNBC. By inhibiting the mTOR pathway, Torin 1 modulates autophagy and apoptosis. Current research highlights its efficacy in combination therapies, such as with chloroquine, where it synergistically induces autophagic and apoptotic cell death in specific TNBC subtypes. This review summarizes the pharmacological activity, molecular mechanisms, limitations, and future perspectives of Torin 1 and related mTOR inhibitors in the context of TNBC treatment, based on recent literature.
1. Introduction
Triple-negative breast cancer (TNBC) accounts for a significant proportion of breast cancer-related mortality due to its aggressive growth, high recurrence rate, and rapid metastasis. Because TNBC lacks estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2), patients do not respond to conventional hormone or HER2-targeted therapies [1]. Consequently, there is an urgent clinical need to identify novel druggable targets and small-molecule compounds to combat this disease.
Recent therapeutic strategies have focused on targeting regulated cell death (RCD) subroutines, which include apoptosis, autophagy-dependent cell death, mitotic catastrophe, necroptosis, and ferroptosis [1]. Autophagy, in particular, acts as a double-edged sword in cancer; it can either promote tumor cell survival by recycling nutrients under stress or induce programmed cell death when overactivated [1]. The mammalian target of rapamycin (mTOR) is a central negative regulator of autophagy. Small-molecule mTOR inhibitors, such as Torin 1 (TOR), have thus garnered substantial interest in oncology research as agents capable of modulating RCD to eliminate TNBC cells [1].
2. Pharmacological Activity
Torin 1 exhibits notable pharmacological activity against TNBC by actively triggering regulated cell death. While monotherapy with targeted agents can sometimes yield limited efficacy, Torin 1 has shown remarkable pharmacological synergy in combination regimens. Specifically, the combined application of Torin 1 and chloroquine (CQ) exerts a potent half-lethal effect on TNBC cells [1]. This combination actively induces both autophagic-dependent cell death and apoptotic cell death [1]. Furthermore, studies indicate that this specific combination therapy is highly active against the BL2 (basal-like 2) molecular subtype of TNBC, highlighting its potential for subtype-specific precision oncology [1].
3. Molecular Mechanism of Action
The primary molecular mechanism of Torin 1 involves the direct inhibition of mTOR, a critical kinase that exists in two complexes (mTORC1 and mTORC2) and serves as a sensor for cellular energy and nutrition [1]. Under normal physiological conditions, the PI3KC1-Akt-mTORC1 signaling pathway inhibits the occurrence of autophagy. By inhibiting mTOR, Torin 1 relieves this suppression, leading to the indirect activation of the unc-51-like kinase 1 (ULK1) complex [1]. The activation of the ULK1 complex subsequently promotes the formation of autophagosomes and drives the cell toward autophagy-dependent cell death [1].
In the context of combination therapy, Torin 1 (an mTOR inhibitor) is paired with chloroquine (a Toll-like receptor/autophagy inhibitor). This pharmacological regulation coordinates the induction of autophagic cell death alongside apoptotic cell death, effectively dismantling the cancer cell's survival mechanisms [1]. Additionally, related chemical analogues, such as Torin 2, demonstrate that simultaneously inhibiting mTOR and other PI3K-like kinases (PIKKs) leads to the accumulation of single-stranded DNA (ssDNA) and replication stress, ultimately causing mitotic catastrophe and the death of TNBC tumor cells [1].
4. Structure-Activity Relationship (SAR)
While the provided literature extensively covers the pathway targets of Torin 1, specific structural modifications and detailed structure-activity relationship (SAR) data for Torin 1 itself are limited in the current text. However, the literature emphasizes that the chemical scaffold of Torin-class molecules (including Torin 1 and its analogue Torin 2) is designed to competitively bind and inhibit the kinase domains of mTOR and related PI3K-like kinases (PIKKs) [1]. The ability of these compounds to dually target mTOR and PIKKs is structurally crucial for inducing replication disasters and mitotic catastrophes in highly proliferative TNBC cells [1].
5. Current Limitations
Despite the promising mechanisms of Torin 1, several limitations hinder the clinical translation of small-molecule mTOR inhibitors in TNBC. First, autophagy is a highly complex process that can act as a survival mechanism for tumor cells under metabolic stress; thus, improper modulation might inadvertently protect cancer cells rather than kill them [1]. Second, small-molecule monotherapies are highly susceptible to drug-resistant mutations. TNBC cells can develop multidrug resistance sites shortly after the administration of targeted small-molecule drugs [1]. Finally, the efficacy of drugs like Torin 1 heavily relies on precise combination schemes. If not administered according to optimized standard protocols, the side effects of the drugs can increase significantly, lowering patient tolerance and resulting in poor therapeutic outcomes [1].
6. Future Perspectives
The future of Torin 1 and related mTOR inhibitors in oncology lies in rational combination therapies and precision medicine. The successful synergistic application of Torin 1 with chloroquine to induce dual autophagic and apoptotic death provides a strong rationale for exploring other combinatorial strategies that merge autophagy inducers with apoptosis or ferroptosis modulators [1]. Furthermore, developing combinations of existing mTOR/PIKK inhibitors or Torin analogues is viewed as a potentially highly effective strategy to force TNBC cells into mitotic catastrophe [1].
Additionally, leveraging molecular subtyping tools (such as the Lehmann Classifier) will allow clinicians to match specific TNBC subtypes (e.g., the BL2 subtype, which shows sensitivity to the Torin 1/chloroquine combination) with the most appropriate targeted therapies. As research into the biological behavior of TNBC deepens, the application of Torin 1 in individualized, low-resistance, and high-efficacy treatment regimens will likely expand [1].
